Vaccine shows promise for kidney cancer
Results of a phase III study from Germany in this week’s issue of THE LANCET suggest that a tumour-based vaccine could reduce disease recurrence and increase survival of patients who have had surgery for kidney cancer.
3% of cancer occurs in the kidney, with around 12,000 renal-cancer deaths a year in the USA. Removal of part or all of the kidney (nephrectomy) is the standard treatment for renal cancer, although other treatments after surgery (eg, radiotherapy, chemotherapy) are not effective. Around half of patients with renal cancer will have disease recurrence within 5 years.
Dieter Jocham from the University of Lubeck Medical School, Germany, and colleagues studied 558 patients from 55 medical centres in Germany with a renal tumour scheduled for nephrectomy. Before surgery, all patients were randomised to receive autologous renal tumour cell vaccine (six injections in the upper arm at 4-week intervals after surgery; the vaccine group) or no additional treatment (the control group).
Data were available for 379 patients. 5-year progression-free survival rates were 77% in the vaccine group and 68% in the control group. The vaccine was well tolerated, with only 12 adverse events associated with the treatment. The authors conclude that the vaccine can now be considered for renal cancer patients with tumours larger than 2.5 cm who have undergone nephrectomy.
Referring to Jocham and colleagues’ study as an ‘immunological breakthrough’, Mayer Fishman and Scott Antonia from H Lee Moffitt Cancer Center and Research Institute, Tampa, USA, state in an accompanying Commentary (p 583): ‘‘[Jocham and colleagues’] carefully collected data are part of a broadening base of clinical observations of the potential to affect the biology of a solid tumour with non-toxic readministration of autologous tumour-derived material’ The key milestone is the suggestion of a fixed point-a non-toxic vaccine with a biological clinically relevant effect in T2-3N0 renal cancer-around which innovations can be built. Such a milestone can serve as a concrete step towards making adjuvant treatment of renal cancer a routine and effective intervention.’
Media Contact
More Information:
http://www.thelancet.comAll latest news from the category: Health and Medicine
This subject area encompasses research and studies in the field of human medicine.
Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.
Newest articles
Novel catalyst for charge separation in photocatalytic water splitting
A research team led by Prof. JIANG Hailong, Prof. LUO Yi, and Prof. JIANG Jun from the University of Science and Technology of China (USTC) discovered a metal-organic framework (MOF)…
Finding a missing piece for neurodegenerative disease research
Research led by the University of Michigan has provided compelling evidence that could solve a fundamental mystery in the makeup of fibrils that play a role in Alzheimer’s, Parkinson’s and…
BESSY II: New procedure for better thermoplastics
Thermoplastic blends, produced by a new process, have better resilience. Now, experiments at the IRIS beamline show, why: nanocrystalline layers increase their performance. Bio-based thermoplastics are produced from renewable organic…